Recipharm publishes Annual Report 2019

Recipharm publishes its 2019 Annual Report today. The report summarises the business and highlights for 2019 and gives insights into the company’s strategy.

The report is attached through the link at the end of the press release and it is also presented on

To order a printed copy, please send an email with your name and address to


For more information please visit or contact:, telephone: +46 8 602 52 00 


About Recipharm
Recipharm is a leading Contract Development and Manufacturing Organisation (CDMO) in the pharmaceutical industry employing almost 9,000 employees. Recipharm offers manufacturing services of pharmaceuticals in various dosage forms, production of clinical trial material and APIs, and pharmaceutical product development. Recipharm manufactures several hundred different products to customers ranging from big pharma to smaller research and development companies. Recipharm’s turnover is approximately SEK 7.5 billion. The company operates development and manufacturing facilities in France, Germany, India, Israel, Italy, Portugal, Spain, Sweden, the UK and the US and is headquartered in Stockholm, Sweden. The Recipharm B-share (RECI B) is listed on Nasdaq Stockholm.

For more information on Recipharm and our services, please visit